Radiotherapy, immunotherapy and DNA repair inhibitors: a winning combination towards the oncology of the future

Onxeo, a biopharmaceutical company specialising in the development of innovative drugs, and the Institut Curie are launching a series of studies aimed at investigating the benefits of combining radiotherapy, DNA repair inhibitors and immunotherapy.